Features of Steven L. Hauser's professional activity regarding the application of rehabilitation tools for patients with multiple sclerosis

Abstract

The article, based on the study and synthesis of scientific literature, establishes that the incidence of multiple sclerosis in the world is high, and treatment is long and not always effective. The professional activities of Dr. Stephen L. Hauser are analyzed. The main topic of his research concerns multiple sclerosis. A multicomponent model is used to rehabilitate patients with this disease, including physical therapy to maintain the individual's motor activity and occupational therapy to improve patient performance and safety.
 Dr. Gauser's research has expanded the understanding of the genetic determinants, immune mechanisms, and treatment of multiple sclerosis. His work has led to the development of B-cell therapy for patients with the disease, representing a new approach to treating all forms of the disease and the first therapy with proven efficacy for advanced multiple sclerosis. Dr. Steven Gauser was instrumental in the research and clinical trials that ultimately led to Ocrevus (ocrelizumab), the first drug approved by the Food and Drug Administration for both relapsing-remitting and primary progressive multiple sclerosis patients.
 The development of B-cell therapy for patients with multiple sclerosis in combination with physical rehabilitation has significant benefits and proven efficiency.